Skip to main content
. 2022 Nov 1;86:104322. doi: 10.1016/j.ebiom.2022.104322

Fig. 6.

Fig. 6

Frequency of the most common adverse events of any cause (safety population). Patients could have more than one adverse event. Adverse events were classified using MedDRA version 23.0. ASAQ, artesunate-amodiaquine; PA, pyronaridine-artesunate; FPV + NTZ, favipiravir plus nitazoxanide; SOF-DCV, sofosbuvir-daclatasvir.